Can You Take Iron dextran with PNV 27-Ca/Fe/FA?

The recommended maximum number of medicines in the 'iron preparations' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'iron preparations' category:

• iron dextran
• PNV 27-Ca/Fe/FA (multivitamin, prenatal)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

Food may reduce the absorption and blood levels of multivitamin, prenatal. In addition, some oral medications can also interfere with multivitamin, prenatal absorption into the bloodstream, which may make the medication less effective in treating your condition. Likewise, multivitamin, prenatal may interfere with the absorption of other orally administered medications. You should take multivitamin, prenatal on an empty stomach at least one hour before or two hours after a meal. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Talk to your doctor or pharmacist if you have questions about how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

There is no excretory mechanism for iron. Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions. Clinical monitoring of erythropoietic function and ferritin levels is recommended.

There is no excretory mechanism for iron. Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions. Clinical monitoring of erythropoietic function and ferritin levels is recommended.

Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver. Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes. Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.

Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness. Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.

Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness. Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.

Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration. Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma. Epinephrine should be immediately available in the event of acute hypersensitivity reactions.

Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration. Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma. Epinephrine should be immediately available in the event of acute hypersensitivity reactions.

Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy. Hypotension and flushing have been reported and are thought to be infusion- rate related. Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.

Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.